Denali's Avlayah Approved as First Agent for Hunter Syndrome Neurologic Symptoms

The FDA has approved Denali's tividenofusp alfa-eknm (Avlayah) to treat neurologic manifestations of Hunter syndrome, a rare X-linked lysosomal storage disorder affecting approximately 500 people in the United States.1 The approval marks the first time a product has cleared regulatory review specifically for the neurologic dimension of the disease, a distinction with meaningful implications for how rare disease programs are designed, evaluated, and brought to market.

Hunter syndrome results from the accumulation of glycosaminoglycans within cellular lysosomes, disrupting physical and mental development by causing progressive abnormalities across the skeleton, heart, respiratory system, brain, and other organs.1 Avlayah is administered as a once-weekly intravenous infusion. The approved indication covers pediatric patients weighing at least 5 kg, when treatment is initiated prior to advanced neurologic impairment, in either a presymptomatic or symptomatic state.

What Does the Approval Pathway Tell Us About Evolving Regulatory Standards?

The agency granted accelerated approval based on a surrogate endpoint rather than direct clinical outcomes data.1 Specifically, reduction of heparan sulfate in cerebrospinal fluid served as the basis for approval, with the review team determining this measure was reasonably likely to predict clinical benefit. Heparan sulfate is among the glycosaminoglycans that accumulate in the disorder and is linked to organ damage occurring in early childhood.

CDER Director Tracy Beth Hoeg, MD, PhD, stated, in a press release,1 "This accelerated approval was based on a surrogate endpoint: reduction of cerebrospinal fluid heparan sulfate, which the review team determined was reasonably likely to predict Avlayah's clinical benefit. Heparan sulfate is one of the glycosaminoglycans that accumulates in the body in this disorder and is linked to the organ damage that occurs in early childhood."

The sponsor submitted results from a phase I/II multi-cohort, single-arm, open-label trial enrolling 47 pediatric patients aged 3 months to 13 years.1 Among the 44 patients with measurements at week 24, the average reduction from baseline in cerebrospinal fluid heparan sulfate was 91%, with individual results ranging from 72% to 98%. At baseline, no patients had levels below the established upper limit of normal; by week 24, 93% of patients with available measurements had fallen below that threshold.

The study design, open-label, single-arm, with a biochemical surrogate as the primary endpoint, reflects the practical constraints of developing therapies for conditions with very small patient populations.1 This is territory familiar to rare disease teams, where conventional randomized controlled trial structures are often ethically or operationally impractical in the presymptomatic population.

FDA Commissioner Marty Makary, MD, MPH, said, in the press release,1 "The FDA is capable of doing two things: one, exercising regulatory flexibility; and two, complying with our obligation under the law to approve drugs based on 'substantial evidence' of effectiveness. We will continue to do everything we can to accelerate treatments for rare diseases."

What Comes Next for Post-Market Confirmation?

Accelerated approval carries with it the obligation to confirm clinical benefit through post-market study. 1 A randomized clinical trial to evaluate Avlayah's clinical benefit is currently underway and reported to be more than 95% enrolled. The transition from accelerated to full approval will depend on that trial's outcome, making robust process consistency and supply reliability during the post-market period operationally significant.

Dr. Hoeg noted,1 "Families with young children with Hunter syndrome will have access to a product that may favorably alter the course of the disease at the crucial time in life when there is the greatest potential for benefit."

From a safety and pharmacovigilance standpoint, the labeling carries a boxed warning for allergic reactions, including anaphylaxis, requiring that therapy be initiated in a healthcare setting with appropriate monitoring.1 The adverse event profile identified in the trial includes upper respiratory tract infection, ear infection, fever, anemia, cough, vomiting, diarrhea, rash, COVID-19, runny nose, nasal congestion, fall, headache, skin abrasion, and hives. Two safety signals warrant ongoing monitoring protocols: anemia, with hemoglobin assessments required at baseline, three months post-initiation, and periodically thereafter; and membranous nephropathy, with kidney function and urine protein monitoring indicated throughout treatment.

The program received breakthrough, fast track, priority review, and orphan drug designations.1 The approval reinforces that the surrogate-to-clinical-endpoint pathway, when properly constructed and transparently communicated, continues to be a viable route to market for conditions which waiting for long-term outcomes data is not a defensible option.

How Does the FDA's Priority Voucher Program Intersect with Rare Disease Development?

The Avlayah approval arrives at a moment of broader regulatory recalibration.2 The FDA's Commissioner's National Priority Voucher pilot program, introduced an ultra-fast review pathway for drugs and biological products of strategic national importance, including Aylayah. Since its launch, the agency has awarded vouchers for 18 products and granted four approvals, including two oncology drugs reviewed in 44 and 55 days after filing. A public hearing on program implementation is scheduled for June 12, with written comments accepted through June 27.

References

1. US Food and Drug Administration. FDA approves drug to treat neurologic manifestations of Hunter syndrome. Silver Spring (MD): US Food and Drug Administration; 2026 Mar 25 [cited 2026 Mar 26]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome
2. ​ US Food and Drug Administration. FDA schedules public meeting on the Commissioner’s National Priority Voucher Pilot Program. Silver Spring (MD): US Food and Drug Administration; 2026 Mar 20 [cited 2026 Mar 26]. Available from: https://www.fda.gov/news-events/press-announcements/fda-schedules-public-meeting-commissioners-national-priority-voucher-pilot-program